Exposure to Medical Radiation during Fetal Life, Childhood and Adolescence and Risk of Brain Tumor in Young Age: Results from The MOBI-Kids Case-Control Study.


Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2020
Historique:
received: 14 09 2019
accepted: 20 01 2020
pubmed: 23 3 2020
medline: 19 8 2021
entrez: 23 3 2020
Statut: ppublish

Résumé

We explored the association between ionizing radiation (IR) from pre-natal and post-natal radio-diagnostic procedures and brain cancer risk within the MOBI-kids study. MOBI-kids is an international (Australia, Austria, Canada, France, Germany, Greece, India, Israel, Italy, Japan, Korea, New Zealand, Spain, The Netherlands) case-control study including 899 brain tumor (645 neuroepithelial) cases aged 10-24 years and 1,910 sex-, age-, country-matched controls. Medical radiological history was collected through personal interview. We estimated brain IR dose for each procedure, building a look-up table by age and time period. Lifetime cumulative doses were calculated using 2 and 5 years lags from the diagnostic date. Risk was estimated using conditional logistic regression. Neurological, psychological and genetic conditions were evaluated as potential confounders. The main analyses focused on neuroepithelial tumors. Overall, doses were very low, with a skewed distribution (median 0.02 mGy, maximum 217 mGy). ORs for post-natal exposure were generally below 1. ORs were increased in the highest dose categories both for post and pre-natal exposures: 1.63 (95% CI 0.44-6.00) and 1.55 (0.57-4.23), respectively, based on very small numbers of cases. The change in risk estimates after adjustment for medical conditions was modest. There was little evidence for an association between IR from radio-diagnostic procedures and brain tumor risk in children and adolescents. Though doses were very low, our results suggest a higher risk for pre-natal and early life exposure, in line with current evidence.

Sections du résumé

BACKGROUND
We explored the association between ionizing radiation (IR) from pre-natal and post-natal radio-diagnostic procedures and brain cancer risk within the MOBI-kids study.
METHODS
MOBI-kids is an international (Australia, Austria, Canada, France, Germany, Greece, India, Israel, Italy, Japan, Korea, New Zealand, Spain, The Netherlands) case-control study including 899 brain tumor (645 neuroepithelial) cases aged 10-24 years and 1,910 sex-, age-, country-matched controls. Medical radiological history was collected through personal interview. We estimated brain IR dose for each procedure, building a look-up table by age and time period. Lifetime cumulative doses were calculated using 2 and 5 years lags from the diagnostic date. Risk was estimated using conditional logistic regression. Neurological, psychological and genetic conditions were evaluated as potential confounders. The main analyses focused on neuroepithelial tumors.
RESULTS
Overall, doses were very low, with a skewed distribution (median 0.02 mGy, maximum 217 mGy). ORs for post-natal exposure were generally below 1. ORs were increased in the highest dose categories both for post and pre-natal exposures: 1.63 (95% CI 0.44-6.00) and 1.55 (0.57-4.23), respectively, based on very small numbers of cases. The change in risk estimates after adjustment for medical conditions was modest.
CONCLUSIONS
There was little evidence for an association between IR from radio-diagnostic procedures and brain tumor risk in children and adolescents. Though doses were very low, our results suggest a higher risk for pre-natal and early life exposure, in line with current evidence.

Identifiants

pubmed: 32200380
pii: 000506131
doi: 10.1159/000506131
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-355

Subventions

Organisme : CIHR
ID : 110835
Pays : Canada

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Elisa Pasqual (E)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Gemma Castaño-Vinyals (G)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Isabelle Thierry-Chef (I)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Noriko Kojimahara (N)

Department of Public Health, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Malcolm R Sim (MR)

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Michael Kundi (M)

Department of Environmental Health, Center for Public Health, Medical University Vienna, Vienna, Austria.

Daniel Krewski (D)

McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, Ottawa, Ontario, Canada.
Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Franco Momoli (F)

Ottawa Hospital Research Institute, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.

Brigitte Lacour (B)

French National Registry of Childhood Solid Tumors, CHRU, Nancy, France.
Inserm U1153, Center of Research in Epidemiology and StatisticS (CRESS), Paris, France.
Paris University, Epidemiology of Childhood and Adolescent Cancers Team (EPICEA), Paris, France.

Thomas Remen (T)

French National Registry of Childhood Solid Tumors, CHRU, Nancy, France.
Inserm U1153, Center of Research in Epidemiology and StatisticS (CRESS), Paris, France.
Paris University, Epidemiology of Childhood and Adolescent Cancers Team (EPICEA), Paris, France.

Katja Radon (K)

Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany.

Tobias Weinmann (T)

Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany.

Eleni Petridou (E)

Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Unit of Clinical Epidemiology, Karolinska Institute, Stockholm, Sweden.

Maria Moschovi (M)

Haematology-Oncology Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece.

Rajesh Dikshit (R)

Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai, India.

Siegal Sadetski (S)

Cancer and Radiation Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Ramat Gan, Israel.

Milena Maule (M)

Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy.

Mariangela Farinotti (M)

Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Mina Ha (M)

Department of Preventive Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea.

Andrea 't Mannetje (A)

Centre for Public Health Research, Massey University, Wellington, New Zealand.

Juan Alguacil (J)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain.

Nuria Aragonés (N)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Cancer Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain.

Roel Vermeulen (R)

Division Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.

Hans Kromhout (H)

Division Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.

Elisabeth Cardis (E)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain, elisabeth.cardis@isglobal.org.
Universitat Pompeu Fabra (UPF), Barcelona, Spain, elisabeth.cardis@isglobal.org.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, elisabeth.cardis@isglobal.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH